Diagnos (TSE:ADK)
:ADK
Want to see TSE:ADK full AI Analyst Report?
Top Page
Diagnos
(ADK)
Select Model
Select Model
Rating:43Neutral
Price Target:
C$0.23
▼(-36.94% Downside)
Action:Reiterated
Date:06/13/26
The score is held down primarily by weak financial performance (shrinking revenue, large ongoing losses, and persistent cash burn) and a fragile balance sheet with meaningful leverage. Technicals also show a sustained downtrend (below major moving averages and negative MACD), while valuation remains hard to justify given ongoing losses and no dividend support.
Positive Factors
AI-driven CARA screening platform
Diagnos’ CARA AI image‑analysis platform represents a durable, scalable product-led business model: it can be integrated into organized screening workflows and monetized per screening or contracted access, aligning revenue with recurring screening volumes over time.
Negative Factors
Sharply declining revenue
Material multi‑year revenue contraction undermines product-market traction and unit economics. Sustained top-line shrinkage reduces scale benefits, weakens pricing power with customers, and makes path to self-sustaining margins and growth uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
AI-driven CARA screening platform
Diagnos’ CARA AI image‑analysis platform represents a durable, scalable product-led business model: it can be integrated into organized screening workflows and monetized per screening or contracted access, aligning revenue with recurring screening volumes over time.
Read all positive factors
Diagnos (ADK) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$28.30M
Dividend YieldN/A
Average Volume (3M)342.67K
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue Growth-36.92%
EPS Growth13.03%
CountryCA
Employees16
SectorGeneral
Sector StrengthN/A
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.04
Shares Outstanding120,412,550
10 Day Avg. Volume531,548
30 Day Avg. Volume342,665
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)43.19
Price to Sales (P/S)453.09
P/FCF Ratio-7.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Diagnos Business Overview & Revenue Model
Company Description
DIAGNOS Inc. is a technology firm that delivers software-based services across a broad international footprint, encompassing Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. A significant portion of its operations ...
How the Company Makes Money
Diagnos primarily makes money by commercializing its CARA retinal screening platform through arrangements with healthcare organizations and screening programs. Revenue is generated from providing access to the CARA software/AI analysis service use...
Diagnos Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Jun 2023 | Jun 2022 | Mar 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 65.48K | 103.80K | 170.16K | 438.83K | 331.52K |
| Gross Profit | -119.45K | -943.56K | 35.80K | -418.30K | -473.45K |
| EBITDA | -4.13M | -3.56M | -2.45M | -2.10M | -1.93M |
| Net Income | -4.56M | -4.29M | -3.12M | -2.61M | -3.38M |
Balance Sheet | |||||
| Total Assets | 2.39M | 3.64M | 663.79K | 1.54M | 2.43M |
| Cash, Cash Equivalents and Short-Term Investments | 1.93M | 3.24M | 219.01K | 920.91K | 1.87M |
| Total Debt | 1.40M | 3.07M | 3.19M | 1.19M | 337.55K |
| Total Liabilities | 1.70M | 3.40M | 3.72M | 1.66M | 614.78K |
| Stockholders Equity | 686.90K | 233.11K | -3.05M | -113.51K | 1.82M |
Cash Flow | |||||
| Free Cash Flow | -4.01M | -3.65M | -2.16M | -2.07M | -2.66M |
| Operating Cash Flow | -4.00M | -3.64M | -2.15M | -2.04M | -2.64M |
| Investing Cash Flow | 1.56M | -3.11M | -14.02K | 503.52K | -759.98K |
| Financing Cash Flow | 2.66M | 6.62M | 2.08M | 1.60M | 3.83M |
Diagnos Technical Analysis
Positive
0.36
Price Trends
0.22
Positive
0.25
Negative
0.28
Negative
Market Momentum
<0.01
Negative
61.54
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ADK, the sentiment is Positive. The current price of 0.36 is above the 20-day moving average (MA) of 0.22, above the 50-day MA of 0.22, and above the 200-day MA of 0.28, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.54 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ADK.
Diagnos Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
48 Neutral | C$59.11M | -4.49 | -207.53% | ― | 22432.50% | -22.03% | |
43 Neutral | C$28.30M | -5.69 | 3086.87% | ― | -36.92% | 13.03% | |
42 Neutral | C$9.93M | -2.87 | 6239.15% | ― | ― | 68.00% | |
41 Neutral | C$14.49M | -2.53 | ― | ― | 9.06% | -42.75% | |
40 Underperform | C$5.20M | -1.77 | ― | ― | ― | 86.37% | |
| ― | C$6.58M | -4.90 | 527.45% | ― | ― | -21.65% |
* General Sector Average
TSE:ADK
Diagnos
0.24
0.04
23.68%
TSE:AIDR
Rocket Doctor AI
0.61
0.20
48.78%
TSE:CHS
Comprehensive Healthcare Systems Inc
0.50
-0.18
-26.47%
TSE:UDOC
UniDoc Health Corp
0.12
-0.06
-36.11%
TSE:NARA
PanGenomic Health, Inc. Class A
0.37
-0.33
-47.14%
TSE:DMED
DiagnaMed Holdings Corp.
0.05
0.02
66.67%
Diagnos Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Diagnos Advances Global Regulatory Push for Next‑Generation CARA Eye‑Disease Platform
Positive
Apr 8, 2026
Diagnos has reiterated its strategy to expand the CARA AI‑based eye‑disease detection platform across key jurisdictions, with a near‑term focus on securing approvals from regulators in Saudi Arabia, Canada and the U.S. The compan...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Diagnos Renews U.S. FDA Registration and Extends Warrant Expiry
Positive
Apr 1, 2026
Diagnos Inc. has renewed its annual U.S. FDA medical device establishment registration, ensuring continued authorization to market its AI-driven eye health solutions in the American market. The company also confirmed that the legacy version of its...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.